Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.54), in-line with the analyst estimate of ($0.54).

Financial Outlook: The Company believes that, based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements into the fourth quarter of 2026. This expectation excludes any additional potential milestone payments under the Commercialization and Distribution Agreements with Nippon Shinyaku, as well as any strategic use of capital not currently in the Company’s base case planning assumptions.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.